Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital160 AstraZeneca154 Janssen Research & Development, LLC58 Eli Lilly and Company45 Hoffmann-La Roche43
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Chengdu

1307 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
Chinese University of Hong Kong
Not applicable
228
Chengdu
2027-07-01
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2027-01-11
Not yet open
Chunshui He
Observational
600
Beijing, Xiamen, Hangzhou, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu
2027-01-01
Not yet open
West China Hospital
Observational
380
Chengdu
2027-01-01
Not yet open
A Study of TIL in Advanced Solid Tumors (CZ)
NCT07294872Solid Tumor, Adult
Shanghai Juncell Therapeutics
Phase 1
30
Chengdu
2026-12-08
Not yet open
West China Hospital
Not applicable
60
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2026-12-01
Not yet open
Clinical Efficacy of Modified Simiao Yongan Decoction and Endovascular Therapy for Diabetic Foot Ulcers
NCT07808502Diabetic Foot Ulcer, Damp-Heat Toxins Accumulation Syndrome
Chengdu University of Traditional Chinese Medicine
Not applicable
120
Chengdu
2026-12
Not yet open
Eli Lilly and Company
Phase 3
2,115
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan
2026-12
Not yet open
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
Eli Lilly and Company
Phase 3
3,000
Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Liaoyou, Luoyang Shi
2026-12
Not yet open
Bristol-Myers Squibb
Phase 2
80
Changsha Shi, Shanghai, Chengdu, Beijing
2026-11-30
Not yet open
Beijing QL Biopharmaceutical Co.,Ltd
Phase 1
24
Chongqing, Zhengzhou, Chengdu
2026-11-13
Recruiting
West China Hospital
Phase 2
128
Chengdu
2026-11-05
Not yet open
Boehringer Ingelheim
Phase 3
600
Chengdu, Luoyang, Nanjing, Shanghai
2026-11-02
Recruiting
Ruijin Hospital
Phase 1/2
78
Shanghai, Chengdu
2026-11-01
Not yet open
Galderma R&D
Not applicable
326
Chengdu
2026-11
Not yet open
Phase I Study of JY1001 Injection
NCT07848945Pain After Surgery
Jemincare
Phase 1
48
Chengdu
2026-11
Not yet open
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
NCT07875881High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules
Hinova Pharmaceuticals Inc.
Phase 3
1,044
Beijing, Shanghai, Chengdu
2026-10-31
Not yet open
Sichuan University
Phase 2
30
Chengdu
2026-10-31
Recruiting
GST101 in Participants With RAS-Mutant Advanced Solid Tumors
NCT07868172RAS-mutant Advanced Solid Tumors
Genuine Seed Therapeutics (Zhuhai) Co., Ltd.
Phase 1/2
172
Harbin, Wuhan, Jinan, Shanghai, Chengdu, Hangzhou
2026-10-30
Recruiting
Takeda
Phase 2
36
Beijing, Guangdong, Nanning, Wuhan, Xi'an, Jinan, Chengdu, Hangzhou
2026-10-27
Recruiting
Merz North America, Inc.
Not applicable
163
Beijing, Changde, Chengdu, Gaozhou, Hangzhou, Nanjing, Xianyang, Yibin
2026-10-27
Not yet open
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
NCT07842276Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin
DrugsDoxorubicin·Tislelizumab
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2
49
Chengdu
2026-10-18
Recruiting
AstraZeneca
Phase 3
140
Beijing, Bengbu, Changchun, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2026-10-09
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Chengdu, Harbin, Shanghai
2026-10-01
Not yet open
West China Hospital
Not applicable
200
Chengdu
2026-10-01
Not yet open
Mundipharma (China) Pharmaceutical Co. Ltd
Observational
378
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2026-10
Not yet open
Sinovac Biotech Co., Ltd
Phase 4
150
Changsha, Chengdu, Chongqing, Guangzhou, Nanjing, Wuhan
2026-10
Not yet open
Colgate Palmolive
Phase 3
135
Chengdu
2026-10
Not yet open
MRI-Based Neurodevelopmental Risk Stratification in Infants With White Matter Injury
NCT07860749Punctate White Matter Lesions, Neurodevelopmental Outcomes, Preterm Infants
First Affiliated Hospital Xi'an Jiaotong University
Observational
260
Xi'an, Ankang, Chengdu, Hangzhou, Lanzhou, Qinghai, Shanghai, Shijiazhuang
2026-10
Recruiting
Beijing Sungen Biomedical Technology Co., Ltd
Phase 2
129
Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo
2026-09-30
Recruiting
Akeso
Phase 1
243
Harbin, Shanghai, Chengdu
2026-09-30
Recruiting
Galderma R&D
Not applicable
162
Beijing, Nanjing, Chengdu, Hangzhou
2026-09-28
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
369
Guangzhou, Guilin, Nanning, Luoyang, Nanchang, Jinan, Shanghai, Chengdu
2026-09-28
Recruiting
West China Hospital
Phase 2
140
Chengdu
2026-09-28
Recruiting
AstraZeneca
Observational
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2026-09-28
Recruiting
Clarify HPP: Disease Burden of HPP Patients in China
NCT07905287Hypophosphatasia (HPP)
AstraZeneca
Observational
200
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Huai'an
2026-09-26
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
300
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Jiaxing, Jining, Kunming
2026-09-26
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Beijing, Chengdu, Guangdong Province, Guangzhou, Hangzhou, Nanchang, Wuhan, Zhengzhou
2026-09-24
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Jinan, Nanjing, Taiyuan
2026-09-24
Recruiting
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
NCT07715279Calcific Aortic Valve Disease, AORTIC VALVE DISEASES, Aortic Valve Stenosis
DrugVericiguat
West China Hospital
Phase 2
238
Chengdu
2026-09-24
Not yet open
Wang Xin
Phase 2
34
Chengdu
2026-09-20
Recruiting
TransThera Sciences (Nanjing), Inc.
Phase 2
182
Fuzhou, Guangzhou, Wuhan, Nanjing, Nantong, Jinan, Chengdu, Hangzhou
2026-09-18
Recruiting
University of Electronic Science and Technology of China
Not applicable
120
Chengdu
2026-09-18
Recruiting
Boehringer Ingelheim
Phase 3
466
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou
2026-09-17
Recruiting
AstraZeneca
Phase 3
286
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2026-09-17
Recruiting
AstraZeneca
Phase 3
950
Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2026-09-16
Recruiting
AstraZeneca
Phase 3
1,330
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jiaxing
2026-09-15
Not yet open
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
NCT07649421Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
DrugDarolutamide
West China Hospital
Phase 2
254
Chengdu
2026-09-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
300
Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin
2026-09-12
Recruiting
West China Hospital
Not applicable
116
Chengdu
2026-09-10
Recruiting
West China Hospital
Phase 1
15
Chengdu
2026-09-10
Not yet open
West China Hospital
Phase 1/2
45
Chengdu
2026-09-10
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
160
Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Chengdu, Hangzhou
2026-09-10
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-09-10
Recruiting
Wireless Wearable Home Prehabilitation for Older Adults With NSCLC
NCT07809763Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery, Prehabilitation
West China Hospital
Not applicable
196
Chengdu
2026-09-10
Recruiting
West China Hospital
Phase 2
40
Chengdu, Luzhou, Meishan, Nanchong, Suining, Zigong
2026-09-10
Recruiting
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
NCT07807059Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
DrugHRS-4729
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
32
Chengdu
2026-09-09
Not yet open
Shuangyue Liu
Not applicable
30
Hefei, Beijing, Nanjing, Xuzhou, Dalian, Shanghai, Xi’an, Chengdu
2026-09-07
Recruiting
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2026-09-05
Recruiting
Shanghai UniXell Biotechnology Co., Ltd
Phase 1
12
Beijing, Zhengzhou, Chengdu
2026-09-05
Recruiting
AstraZeneca
Not applicable
540
Chengdu, Chifeng, Dongyang, Hefei, Hengyang, Heze, Jiaxing, Langfang
2026-09-05
Recruiting
Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes
NCT07580638T2DM (Type 2 Diabetes Mellitus)
Chipscreen Biosciences, Ltd.
Observational
3,550
Beijing, Chengdu
2026-09-04
Not yet open
Sphere-9 PAF China Study
NCT07789925Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
180
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin
2026-09-02
Not yet open
Heated Humidified Oxygen in PACU Patients
NCT07778420Hypoxemia, Postoperative Complications, Anesthesia Recovery Period
Second Affiliated Hospital of Xi'an Jiaotong University
Not applicable
2,000
Luoyang, Xi'an, Xianyang, Chengdu
2026-09-01
Not yet open
Du Zhenggui
Observational
268
Chengdu
2026-09-01
Not yet open
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
NCT07175389Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
DrugSerplulimab
West China Hospital
Phase 1/2
10
Chengdu
2026-09-01
Not yet open
Study of SG301 for Renal AMR After Transplantation
NCT07764627Antibody Mediated Rejection
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
10
Guangzhou, Nanning, Zhengzhou, Changsha, Jinan, Chengdu, Hangzhou
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2026-09-01
Recruiting
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
DrugMazdutide
West China Hospital
Phase 4
60
Hefei, Beijing, Chongqing, Chengdu
2026-09-01
Recruiting
Jiyan Liu
Phase 1
9
Chengdu
2026-09-01
Recruiting
Sichuan Academy of Medical Sciences
Not applicable
136
Chengdu
2026-09-01
Active, closed
Pain During Heat Treatment for Lower Extremity Varicose Veins: Radiofrequency vs. Microwave
NCT07907315Lower Extremity Varicose Veins, Radiofrequency Ablation, Microwave Ablation, Pain Measurement
Chunshui He
Observational
130
Chengdu
2026-09-01
Not yet open
Zhejiang Cancer Hospital
Phase 3
140
Guangzhou, Jiangmen, Wuhan, Changsha, Ganzhou, Jinan, Qingdao, Chengdu
2026-09
Not yet open
Shandong Suncadia Medicine Co., Ltd.
Phase 2
60
Chengdu
2026-09
Not yet open
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
NCT07833098Hypertension, Resistant Hypertension, Uncontrolled Hypertension
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 2
240
Baotou, Beijing, Changsha, Chengdu, Chongqing, Daqing, Hebei, Hengyang
2026-09
Not yet open
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Recruiting
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changde, Changlexi, Changsha, Chengdu, Dalian
2026-08-31
Recruiting
Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT07076836Lung Cancer (NSCLC), Immune Checkpoint Blockade, Electroacupuncture
West China Hospital
Not applicable
82
Chengdu
2026-08-31
Not yet open
Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
NCT07797075Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
West China Hospital
Not applicable
222
Chengdu
2026-08-31
Not yet open
Rehabilitation With Wearable Monitors for Post-Lung Cancer Surgery
NCT07733492Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
West China Hospital
Not applicable
126
Chengdu
2026-08-31
Not yet open
Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer
NCT07811076Locally Advanced Rectal Cancer (LARC)
Xuelei Ma MD
Phase 1/2
140
Chengdu
2026-08-31
Recruiting
Online Sharing for Head & Neck Cancer Support
NCT07766226Head and Neck Squamous Cell Carcinoma
West China Hospital
Not applicable
120
Chengdu
2026-08-28
Not yet open
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Recruiting
Eli Lilly and Company
Phase 3
2,001
Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin
2026-08-26
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
36
Chengdu
2026-08-25
Recruiting
Ipsen
Phase 3
160
Guangzhou, Changsha, Nanjing, Wuxi, Jing’an, Chengdu, Hangzhou, Beijing
2026-08-25
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Baoding, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu
2026-08-24
Recruiting
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Recruiting
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Recruiting
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Not yet open
Sichuan Cancer Hospital and Research Institute
Phase 2
43
Chengdu
2026-08-20
Recruiting
AstraZeneca
Phase 3
1,500
Beijing, Cangzhou, Changchun, Chengdu, Danyang, Ganzhou, Guangzhou, Huizhou
2026-08-20
Recruiting
DEC003M in Prostate Cancer
NCT07657806Advanced Prostate Cancer
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Beijing, Suzhou, Chengdu, Hangzhou, Wenzhou, Chongqing
2026-08-19
Recruiting
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Not yet open
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase 1/2
36
Chengdu
2026-08-15
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Changchun, Chengdu, Chongqing, Fuzhou, Ha’erbin, Jinan, Kunming, Luoyang
2026-08-13
Not yet open
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
NCT07751315Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Qilu Pharmaceutical Co., Ltd.
Phase 1
64
Chengdu
2026-08-11
Recruiting
Eli Lilly and Company
Phase 2
606
Baotou, Beijing, Chengdu, Guangzhou, Jiangyin, Jinan, Pingxiang, Shanghai
2026-08-07
Recruiting
Vifor Fresenius Medical Care Renal Pharma
Phase 2
18
Chengdu, Guangzhou, Hangzhou, Shanghai, Wuhan, Xi'an
2026-08-04
Recruiting
Beijing Tiantan Hospital
Observational
3,000
Beijing, Zhengzhou, Wuhan, Suzhou, Nanchang, Shanghai, Chengdu, Hangzhou
2026-08-03
Not yet open
West China Hospital
Phase 2
49
Chengdu
2026-08-01
Not yet open
Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis
NCT07587671Liver Cirrhosis, Portal Hypertension, Gastroesophageal Varices Bleeding, Esophageal Varices
West China Hospital
Not applicable
240
Chengdu, Chongqing, Xiamen
2026-08-01
Recruiting
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
NCT07763301Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC)
DrugYMN-136 Vaccine
West China Hospital
Phase 1
9
Chengdu
2026-08-01
Not yet open
Beijing University of Chinese Medicine
Not applicable
400
Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu
2026-08-01
Not yet open
West China Hospital
Phase 2
25
Chengdu
2026-08-01
Recruiting
The Effect and Mechanism of taVNS in Modulating Human Social Attention
NCT07798349Healthy Adult, Role of Vagal Stimulation in Oxytocin Release, Role of Vagal Stimulation in Social Attention
University of Electronic Science and Technology of China
Not applicable
120
Chengdu
2026-08-01
Not yet open
West China Hospital
Phase 2
66
Chengdu
2026-08
Not yet open
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
32
Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2026-08
Not yet open
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Not yet open
Chongqing Jinsaixing Medical Technology Co., Ltd
Observational
570
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Changchun, Shanghai, Chengdu
2026-07-31
Not yet open
YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases
NCT07610707Colorectal Cancer With Liver Metastatic
DrugYMN-A02
West China Hospital
Phase 1
10
Chengdu
2026-07-30
Recruiting
Turun Song
Phase 4
50
Chengdu
2026-07-30
Not yet open
YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
NCT07580261Hepatocellular Carcinoma
DrugYMN-A02
West China Hospital
Phase 1
10
Chengdu
2026-07-30
Recruiting
Janssen Research & Development, LLC
Phase 2
68
Beijing, Cheng Du Shi, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
2026-07-28
Recruiting
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chengdu, Shanghai
2026-07-27
Recruiting
UCB Biopharma SRL
Phase 2
402
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Shijiazhuang, Yangzhou SHI
2026-07-27
Recruiting
GlaxoSmithKline
Phase 3
800
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Wuhan
2026-07-27
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1
108
Chengdu
2026-07-23
Recruiting
Jiyan Liu
Phase 2
60
Chengdu
2026-07-22
Recruiting
Sichuan University
Early Phase 1
10
Chengdu
2026-07-21
Recruiting
Sichuan Provincial People's Hospital
Phase 4
10
Chengdu
2026-07-20
Recruiting
West China Hospital
Phase 2
90
Chengdu
2026-07-20
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
19
Beijing, Chengdu, Dongguan, Jinan, Shanghai, Shijiazhuang, Taiyuan, Wenzhou
2026-07-20
Recruiting
Qiang Hu
Not applicable
200
Chengdu
2026-07-20
Recruiting
AstraZeneca
Phase 3
915
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2026-07-16
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
Recruiting
West China Hospital
Phase 1
18
Chengdu
2026-07-13
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Guangzhou, Harbin, Zhengzhou, Chengdu
2026-07-10
Recruiting
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
48
Chengdu
2026-07-09
Recruiting
Ausper Biopharma Co., Ltd.
Phase 1
32
Chongqing, Zhengzhou, Shanghai, Chengdu, Hangzhou
2026-07-09
Recruiting
AstraZeneca
Phase 3
900
Binzhou, Changsha, Chengdu, Hangzhou, Jinan, Liaocheng, Liuzhou, Luoyang
2026-07-06
Recruiting
AstraZeneca
Phase 3
800
Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
84
Anyang, Beijing, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2026-07-05
By invitation
Non-surgical Management After NIT for dMMR/MSI-H GC
NCT07646574Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy
Yong Zhou
Observational
12
Chengdu
2026-07-01
Not yet open
West China Hospital
Phase 4
110
Chengdu
2026-07-01
Not yet open
Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients
NCT07656493Invasive Fungal Infection, Solid Organ Transplantation, Opportunistic Infections
DrugsAzoles·Echinocandins·Liposomal Amphotericin B
Sichuan Provincial People's Hospital
Observational
120
Chengdu
2026-07-01
Not yet open
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
NCT07655661Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsTislelizumab·Capecitabine·Oxaliplatin
Ming Liu
Phase 2
52
Chengdu
2026-07-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
By invitation
Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant
NCT07747194Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT)
Xiao Wang
Not applicable
80
Chengdu
2026-07-01
By invitation
Compassionate Administration of ZVS101e for Extended Treatment
NCT07307469Bietti Crystalline Corneoretinal Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Not applicable
32
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2026-07
Not yet open
Different Pressure Tissue Flossing Combined With Exercise for Chronic Ankle Instability
NCT07667816Chronic Ankle Instability, Ankle Instability
Chengdu Sport University
Not applicable
48
Chengdu
2026-07
Not yet open
Sichuan University
Observational
200
Chengdu
2026-06-30
Not yet open
Sichuan University
Observational
500
Chengdu
2026-06-30
Not yet open
Sichuan University
Phase 1
21
Chengdu
2026-06-30
Recruiting
Chengdu Suncadia Medicine Co., Ltd.
Phase 1
180
Chengdu
2026-06-30
Recruiting
Peking University Third Hospital
Observational
114
Beijing, Cangzhou, Chengdu
2026-06-30
Recruiting
West China Hospital
Phase 2
9
Chengdu
2026-06-29
Recruiting
AstraZeneca
Phase 3
4,500
Binzhou, Chengdu, Deyang, Ganzhou, Guangzhou, Haikou, Hangzhou, Huaian
2026-06-29
Recruiting
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Recruiting
AstraZeneca
Phase 2
84
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot
2026-06-24
Recruiting
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2026-06-20
Not yet open
Sichuan University
Phase 1
9
Chengdu
2026-06-20
Not yet open
West China Hospital
Observational
150
Chengdu
2026-06-20
Recruiting
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2026-06-20
Recruiting
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2026-06-20
Recruiting
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2026-06-20
Recruiting
West China Second University Hospital
Not applicable
62
Hefei, Nanning, Guiyang, Zunyi, Nanchang, Xi'an, Chengdu, Ürümqi
2026-06-19
Not yet open
ScinnoHub Pharmaceutical Co., Ltd.
Phase 2
30
Foshan, Guangzhou, Maoming, Liuzhou, Nanning, Haikou, Chengdu
2026-06-18
Not yet open
EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allo-HSCT
NCT07674199Patients After Hematopoietic Stem Cell Transplantation
DrugEBV mRNA vaccine
The General Hospital of Western Theater Command
Early Phase 1
20
Chengdu
2026-06-18
Recruiting
Full-Course ECMO Strategy for Moderate-to-Severe ARDS
NCT07726953Acute Respiratory Distress Syndrome
Southeast University, China
Not applicable
500
Beijing, Changchun, Chengdu, Chenzhou, Dalian, Fuzhou, Guangzhou, Hangzhou
2026-06-16
Recruiting
Immune Mechanisms and ECMO Strategies for Moderate-to-Severe ARDS
NCT07726940Acute Respiratory Distress Syndrome (ARDS)
Southeast University, China
Observational
1,776
Beijing, Fuzhou, Nanjing, Jinan, Chengdu, Hangzhou, Changchun, Chenzhou
2026-06-16
Recruiting
Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
NCT07656909Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon
DrugsRapamycin·Sirolimus
Yi Ji
Phase 2/3
76
Chengdu
2026-06-16
Recruiting
Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis
NCT07567235Radiation-Induced Skin Fibrosis, Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 1
9
Chengdu
2026-06-15
Recruiting
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
NCT07606937Relapsed/Refractory Large B-cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Early Phase 1
12
Beijing, Guangzhou, Suzhou, Shanghai, Chengdu, Tianjin
2026-06-12
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Recruiting
AstraZeneca
Not applicable
500
Beijing, Cangzhou, Changsha, Chengdu, Chongqing, Guangzhou, Kunming, Quanzhou
2026-06-10
Recruiting
Akkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury
NCT07635277Radiation-Induced Skin Injury
West China Hospital
Phase 1
40
Chengdu
2026-06-07
Recruiting
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
NCT07553351Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children, Growth Hormone Deficiency, Pediatric
Kexing Biopharm Co., Ltd.
Phase 3
192
Chengdu
2026-06-06
Not yet open
Akeso
Phase 1/2
286
Beijing, Harbin, Chengdu
2026-06-06
Recruiting
West China Hospital
Phase 1
54
Chengdu
2026-06-05
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
232
Chongqing, Guangzhou, Chengdu, Jiancheng
2026-06-04
Active, closed
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer
NCT07635290Previously Treated, Advanced, Biliary Tract Cancers
DrugsAnlotinib·Cadonilimab
West China Hospital
Phase 2
26
Chengdu
2026-06-03
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Chengdu, Beijing, Jinan, Shanghai, Suzhou, Wuhan
2026-06-03
Recruiting
AstraZeneca
Not applicable
1,000
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou
2026-06-02
Recruiting
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Shijiazhuang, Chengdu, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2026-06-01
Not yet open
West China Hospital
Observational
70
Chengdu
2026-06-01
Active, closed
LLMs Improve Patient Understanding of Ultrasound Reports
NCT07647536Patient Understanding of Ultrasound Reports
Lu Wang
Not applicable
660
Chengdu
2026-06-01
Not yet open
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
NCT07615894Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
WestVac Biopharma Co., Ltd.
Phase 1
9
Chengdu
2026-06-01
Recruiting
Sichuan Academy of Medical Sciences
Not applicable
80
Chengdu
2026-06-01
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Beijing, Zhengzhou, Nanjing, Shanghai, Chengdu
2026-06-01
Not yet open
CLASSYS Inc.
Not applicable
252
Chengdu, Chongqing, Hebei, Shanghai
2026-06
Recruiting
West China Hospital
Phase 1/2
20
Chengdu
2026-06
Not yet open
Treatment of Recurrent/Metastatic Head and Neck Cancer
NCT07601204Recurrent/Metastatic Head and Neck Cancer
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
128
Beijing, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Taiyuan, Chengdu
2026-06
Not yet open
Sichuan Provincial People's Hospital
Phase 4
3,836
Chengdu
2026-06
Not yet open
Beijing Hospital of Traditional Chinese Medicine
Phase 3
636
Beijing, Chengdu, Chongqing, Guangzhou, Guizhou, Haozhou, Hebei, Heilongjiang
2026-05-31
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing
2026-05-31
Not yet open
Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients
NCT07607236Sarcopenia, Kidney Transplantation, Muscle Wasting
Sichuan Provincial People's Hospital
Observational
140
Chengdu
2026-05-30
Not yet open
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
Active, closed
Beijing QL Biopharmaceutical Co.,Ltd
Phase 1
60
Chengdu
2026-05-27
Recruiting
UCB Biopharma SRL
Phase 3
120
Beijing, Chengdu, Chongqing, Nanchang, Suzhou
2026-05-27
Recruiting
AstraZeneca
Phase 4
100
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2026-05-26
Recruiting
H. Lundbeck A/S
Phase 1
10
Beijing, Shanghai Shi, Chengdu
2026-05-26
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Beijing, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-05-23
Recruiting
Yingyong Zhou,MD,PhD
Phase 2
200
Changsha, Chengdu
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou
2026-05-22
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
200
Changsha, Chengdu
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou
2026-05-21
Recruiting
Jecho Biopharmaceuticals Co., Ltd.
Phase 1
18
Chengdu
2026-05-18
Recruiting
Adaptive DBS for PD
NCT07635823Parkinson Disease(PD)
Beijing Pins Medical Co., Ltd
Not applicable
60
Hefei, Beijing, Guangzhou, Changsha, Nanjing, Jinan, Chengdu
2026-05-16
Recruiting
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
NCT07565740HPV-positive Oropharyngeal Squamous Cell Carcinoma
DrugTislelizumab
West China Hospital
Phase 1
9
Chengdu
2026-05-15
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
Guangzhou, Wuhan, Shanghai, Chengdu
2026-05-14
Recruiting
West China Hospital
Phase 2
30
Chengdu
2026-05-11
Recruiting
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2/3
330
Chengdu
2026-05-11
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-05-10
Active, closed
Chengdu University of Traditional Chinese Medicine
Observational
300
Chengdu
2026-05-08
Recruiting
Eli Lilly and Company
Phase 2
531
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-05-06
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-05-06
Recruiting
AstraZeneca
Phase 3
670
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanjing
2026-05-04
Not yet open
West China Hospital
Phase 3
412
Chengdu
2026-05-01
Not yet open
Chengdu Jinjiang Maternity and Child Health Hospital
Not applicable
270
Chengdu
2026-05-01
Recruiting
Effect of Modified Arm Positioning on Shoulder Pain After Thoracoscopic Lobectomy
NCT07746323Ipsilateral Shoulder Pain, Lung Neoplasms
Chengdu Jinjiang Maternity and Child Health Hospital
Not applicable
270
Chengdu
2026-05-01
Not yet open
West China Hospital
Early Phase 1
10
Chengdu
2026-05-01
Not yet open
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
NCT07561983Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic
DrugTislelizumab
Sichuan Cancer Hospital and Research Institute
Phase 2
39
Chengdu
2026-05-01
Not yet open
Chengdu Jinjiang Maternity and Child Health Hospital
Not applicable
446
Chengdu
2026-05-01
Not yet open
A Study of Ta-NPs Plus Radiotherapy for Locally Recurrent Retroperitoneal Sarcoma
NCT07578506Locally Recurrent Retroperitoneal Soft Tissue Sarcoma
West China Hospital
Phase 1
9
Chengdu
2026-05-01
Not yet open
West China Hospital
Not applicable
1,508
Chengdu
2026-05-01
Not yet open
Xi Wu
Not applicable
99
Chengdu
2026-05
Not yet open
Tingting Luo
Not applicable
108
Chengdu
2026-05
Not yet open
Preoperative Decision-Making in Patients With Pulmonary Nodules Suspected of Lung Cancer
NCT07590596Pulmonary Nodule, Suspected Lung Cancer, Preoperative Decision-Making
Sichuan Cancer Hospital and Research Institute
Observational
200
Chengdu
2026-05
Recruiting
IMP3-saRNA Vaccine in Advanced NSCLC
NCT07561723Non-Small Cell Lung Cancer
West China Hospital
Phase 1
9
Chengdu
2026-04-30
Recruiting
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Recruiting
Eli Lilly and Company
Phase 2
342
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-04-29
Not yet open
West China Hospital
Phase 1
9
Chengdu
2026-04-28
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-04-28
Recruiting
West China Hospital
Phase 1
6
Chengdu
2026-04-28
Recruiting
Hoffmann-La Roche
Phase 3
360
Beijing, Fuzhou, Guangzhou, Chengdu, Tianjin
2026-04-27
Recruiting
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2026-04-26
Recruiting
AstraZeneca
Phase 3
230
Beijing, Bengbu, Cangzhou, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2026-04-24
Recruiting
The General Hospital of Western Theater Command
Early Phase 1
20
Chengdu
2026-04-23
Recruiting
West China Hospital
Phase 1
6
Chengdu
2026-04-23
Recruiting
BioNTech SE
Phase 3
736
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Hefei, Nanchang
2026-04-22
Active, closed
AstraZeneca
Not applicable
4,000
Beijing, Changlexi, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangdong Province
2026-04-21
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
596
Guangzhou, Chengdu
2026-04-21
Recruiting
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
NCT07538479Solid Tumors, Solid Malignancies, Cold Exposure, Immunotherapy
West China Hospital
Phase 1
24
Chengdu
2026-04-20
Not yet open
A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children
NCT07511920Muscular Dystrophy, Becker, Muscular Dystrophy, Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne
West China Second University Hospital
Observational
500
Chengdu
2026-04-20
Recruiting
Wang Xin
Phase 2
64
Chengdu
2026-04-15
Recruiting
Dizal Pharmaceuticals
Phase 1/2
220
Chongqing, Fuzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Chengdu, Taizhou
2026-04-15
Active, closed
Beijing QL Biopharmaceutical Co.,Ltd
Phase 1
40
Xiamen, Jinan, Chengdu
2026-04-13
Recruiting
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
Bo Wu
Not applicable
1,600
Chengdu
2026-04-09
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Chengdu, Tianjin
2026-04-08
Not yet open
Xi Cao
Not applicable
400
Chengdu
2026-04-07
Recruiting
MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
NCT07509333Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
West China Hospital
Not applicable
2,000
Chengdu
2026-04-05
Recruiting
Grid eXplore Mapping Study
NCT07421076Paroxysmal Atrial Fibrillation (PAF)
Abbott Medical Devices
Not applicable
200
Jinan, Chengdu, Hangzhou, Ningbo, Beijing
2026-04-02
Recruiting
Effect of NOTCH2NLC Gene Variations on NIID Clinical Features
NCT07670169Neuronal Intranuclear Inclusion Disease (NIID)
Sichuan Academy of Medical Sciences
Observational
12
Chengdu
2026-04-01
Not yet open
Du Zhenggui
Not applicable
1,366
Chengdu
2026-04-01
Not yet open
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
NCT07480382Initially Unresectable Hepatocellular Carcinoma
DrugsLenvatinib·Tislelizumab
Hong Wu
Not applicable
30
Chengdu
2026-04-01
Recruiting
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-04-01
Recruiting
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
NCT07519486Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2
118
Chengdu
2026-04
Recruiting
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
NCT07595172Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer
DrugsNalirifox·Adebrelimab
West China Hospital
Phase 1/2
55
Chengdu
2026-04
Not yet open
Colgate Palmolive
Phase 3
90
Chengdu
2026-04
Active, closed
ChunBao Li
Not applicable
270
Beijing, Shenzhen, Luoyang, Nanjing, Xi'an, Tai’an, Shanghai, Chengdu
2026-03-30
Not yet open
Sichuan Enray Pharmaceutical Sciences Company
Phase 2
52
Chengdu
2026-03-27
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
180
Dalian, Chengdu
2026-03-27
Recruiting
West China Hospital
Phase 1
9
Chengdu
2026-03-27
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Not yet open
Southwest Hospital, China
Phase 3
488
Baise City, Guilin, Qiannan, Chengdu, Dali, Qujing, Ankang, Anyang
2026-03-25
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Chengdu
2026-03-25
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Fuzhou, Guangzhou, Wuhan, Changsha, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-24
Recruiting
Boehringer Ingelheim
Phase 2
132
Beijing, Chengdu, Guangzhou, Nanchang, Nanjing, Nanning, Shanghai, Sichuan
2026-03-23
Recruiting
Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability
NCT07504731Acute Respiratory Distress Syndrome (ARDS)
Zhongda Hospital
Observational
40
Nanjing, Jinan, Chengdu
2026-03-20
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Active, closed
AstraZeneca
Observational
146
Guangzhou, Shenyang, Jinan, Changchun, Changsha, Chengdu, Haikou, Kunming
2026-03-19
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
64
Chengdu, Tianjin
2026-03-18
Recruiting
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Phase 1
116
Beijing, Chengdu
2026-03-18
Recruiting
Beijing Anzhen Hospital
Not applicable
1,312
Beijing, Chengdu, Ürümqi
2026-03-17
Recruiting
West China Hospital
Phase 2
118
Chengdu
2026-03-16
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
40
Chengdu
2026-03-16
Recruiting
West China Hospital
Phase 3
170
Chengdu
2026-03-15
Recruiting
Sanofi
Phase 2/3
526
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning, Shanghai
2026-03-13
Active, closed
Sanofi
Phase 3
59
Baotou, Beijing, Chengdu, Jinan, Jingzhou, Nanning, Shenyang, Taiyuan
2026-03-12
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Shanghai, Chengdu, Beijing, Langfang
2026-03-12
Recruiting
Simcere Pharmaceutical Co., Ltd
Phase 3
498
Xiamen, Changsha, Chengdu, Hangzhou
2026-03-11
Recruiting
AstraZeneca
Observational
2,100
Beijing, Changsha, Chengdu, Guangzhou, Haerbin, Jinan, Nantong, Shanghai
2026-03-06
Active, closed
West China Hospital
Observational
500
Chengdu
2026-03-06
Not yet open
Heilongjiang Feihe Dairy Co. Ltd.
Not applicable
124
Beijing, Foshan, Zhuhai, Xiangtan, Wuxi, Chengdu
2026-03-05
Recruiting
Incyte Corporation
Phase 3
700
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-03-05
Recruiting
H101 Plus TACE for r/m HNSCC
NCT07398664Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
DrugH101
West China Hospital
Phase 2
20
Chengdu
2026-03-02
Recruiting
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
NCT07413757Non-Small Cell Lung Cancer
AstraZeneca
Observational
590
Chengdu
2026-03-02
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Beijing, Wuhan, Chengdu, Tianjin
2026-03-01
Not yet open
Predicting Hypothermia in Gynecological Laparoscopic Surgery Using Machine Learning
NCT07353528Laparoscopic Surgery, Intraoperative Hypothermia, Gynecological Surgery
Chengdu Jinjiang Maternity and Child Health Hospital
Observational
1,000
Chengdu
2026-03-01
Recruiting
Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
NCT07410715HCC - Hepatocellular Carcinoma, Watch & Wait, Surgery
West China Hospital
Observational
100
Chengdu
2026-03-01
By invitation
West China Hospital
Observational
300
Chengdu
2026-03-01
Recruiting
West China Hospital
Phase 2/3
60
Chengdu
2026-03-01
Recruiting
West China Hospital
Observational
200
Beijing, Xuzhou, Chengdu
2026-03-01
Recruiting
West China Hospital
Not applicable
20
Chengdu
2026-03-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
66
Guangzhou, Zhengzhou, Chengdu, Luzhou, Hangzhou
2026-02-26
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
45
Guangzhou, Zhengzhou, Chengdu
2026-02-26
Recruiting
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3
105
Chengdu, Tianjin
2026-02-13
Recruiting
West China Second University Hospital
Not applicable
120
Chengdu, Guiyang, Hefei, Jiangxi, Kunming, Nanning, Ürümqi, Xi'an
2026-02-13
Recruiting
Gelaspan vs Crystalloid Therapy in Sepsis
NCT07172451Sepsis, Intra-Abdominal Infections
Shanghai Zhongshan Hospital
Phase 4
318
Guangzhou, Nanjing, Suzhou, Xuzhou, Shanghai, Chengdu, Tianjing, Hangzhou
2026-02-13
Recruiting
Jiyan Liu
Phase 1
10
Chengdu
2026-02-12
Recruiting
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chaohu, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou
2026-02-09
Not yet open
West China Hospital
Not applicable
198
Chengdu
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou
2026-02-04
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
111
Chengdu
2026-02-03
Recruiting
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
By invitation
University of Electronic Science and Technology of China
Not applicable
60
Chengdu
2026-02-02
Not yet open
Sichuan University
Phase 2
154
Chengdu
2026-02-01
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Recruiting
West China Hospital
Phase 1/2
33
Chengdu
2026-02
Recruiting
Structured Active Follow-up in Postoperative Management of Thyroid
NCT07589660Patients After Thyroid Surgery
Yu Feng
Not applicable
244
Chengdu
2026-01-31
Recruiting
Xinjiang Medical University
Observational
5,000
Chengdu, Ürümqi
2026-01-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Harbin, Nanchang, Shanghai, Chengdu
2026-01-29
Recruiting
Innovent Biologics Technology Limited (Shanghai R&D Center)
Early Phase 1
300
Chengdu
2026-01-29
Recruiting
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Recruiting
University of Electronic Science and Technology of China
Not applicable
90
Chengdu
2026-01-28
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Recruiting
University of Electronic Science and Technology of China
Not applicable
120
Chengdu
2026-01-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
86
Beijing, Fuzhou, Meizhou, Shanghai, Chengdu
2026-01-22
Recruiting
Fujian Cancer Hospital
Phase 2
2,000
Fuzhou, Chengdu
2026-01-21
Recruiting
Hoffmann-La Roche
Observational
500
Xiamen, Lanzhou, Shijiazhuang, Changchun, Wenzhou, Beijing, Chengdu, Chongqing
2026-01-21
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an
2026-01-20
Recruiting
InventisBio Co., Ltd
Phase 2
222
Chengdu
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hefei, Kunming, Shanghai
2026-01-16
Recruiting
University of Electronic Science and Technology of China
Not applicable
60
Chengdu
2026-01-16
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
Not yet open
Shanghai Institute Of Biological Products
Phase 1/2
36
Chengdu
2026-01-15
Recruiting
Sanofi
Phase 3
160
Beijing, Chengdu, Dongguan, Guangzhou, Jiazhuang, Shenyang
2026-01-14
Recruiting
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07483385Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders
DrugLusutrombopag
The General Hospital of Western Theater Command
Not applicable
45
Chengdu
2026-01-13
Not yet open
Spirulina Derivative for Radiation Esophagitis
NCT07324018Radiation-induced Esophagitis
West China Hospital
Phase 2
70
Chengdu
2026-01-12
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
68
Chengdu
2026-01-10
Recruiting
Novo Nordisk A/S
Phase 3
460
Beijing, Zhengzhou, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2026-01-08
Not yet open
West China Hospital
Observational
3,200
Chengdu
2026-01-01
Recruiting
Acepodia Biotech, Inc.
Phase 1/2
34
Beijing, Chengdu, Hangzhou, Hefei, Shanghai, Taiyuan, Wuhan
2026-01-01
Not yet open
IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial
NCT07336927Acute Ischemic Stroke Due to Medium-vessel-occlusion
Bo Wu
Not applicable
614
Chengdu
2026-01-01
Active, closed
Gamified Neurology Grand Rounds
NCT07419984Education, Medical, Grand Rounds
West China Hospital
Not applicable
240
Chengdu
2026-01-01
Not yet open
UDCA to Prevent Post-TIPS Hepatic Encephalopathy
NCT07273734Hepatic Encephalopathy (HE), TIPS
DrugsLactulose·Ursodeoxycholic Acid·UDCA
West China Hospital
Not applicable
270
Chengdu
2026-01-01
Recruiting
West China Hospital
Early Phase 1
30
Chengdu
2026-01-01
Recruiting
The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms
NCT07310056Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery, Perioperative Management
West China Hospital
Not applicable
126
Chengdu
2026-01-01
Recruiting
West China Hospital
Observational
20
Chengdu
2026-01-01
Not yet open
Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling
NCT06813274Diabetes Mellitus, Diabetic Retinopathy, Cognitive Impairment, Neurovascular Coupling
DrugMecobalamin
Hejiang Ye
Phase 2
160
Chengdu, Deyang, Guangyuan
2026-01-01
Not yet open
Guangzhou University of Traditional Chinese Medicine
Observational
3,000
Beijing, Guangzhou, Weihui, Shanghai, Chengdu
2026-01
Not yet open
Cellular-Level Fluorescence Imaging for Intraoperative Margin Assessment in Breast Cancer
NCT07311317Breast Cancer Early Stage Breast Cancer (Stage 1-3)
West China Hospital
Observational
165
Chengdu
2026-01
Recruiting
The Association Between Primary Aldosteronism and Cognitive Dysfunction
NCT07304674Primary Aldosteronism, Cognitive Dysfunction, Mild Cognitive Impairment (MCI), Dementia
Xinjiang Medical University
Observational
1,000
Chengdu, Ürümqi
2025-12-31
Recruiting
Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention
NCT07848152Transcatheter Mitral Valve Edge-to-Edge Repair System, Biodegradable Patent Foramen Ovale Closure Device
Shanghai Jiao Tong University School of Medicine
Observational
2,200
Lanzhou, Guangzhou, Zhengzhou, Wuhan, Shenyang, Jinan, Chengdu, Kunming
2025-12-30
Recruiting
Xingchen Peng
Not applicable
84
Chengdu
2025-12-30
Recruiting
West China Hospital
Observational
250
Chengdu
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
West China Hospital
Early Phase 1
18
Chengdu
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2
140
Nanjing, Nanchang, Shanghai, Chengdu
2025-12-19
Recruiting
West China Hospital
Phase 1/2
9
Chengdu
2025-12-16
Recruiting
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Not yet open
CAR-T for Claudin18.2 Positive Solid Tumors
NCT07266311Claudin18.2 Positive Advanced Solid Tumors
Chengdu Ucello Biotechnology Co., Ltd.
Early Phase 1
18
Chengdu
2025-12-15
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
DrugIparomlimab and Tuvonralimab
Peking University
Phase 2
106
Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Not yet open
CD19/BCMA CAR-T for SLE
NCT07266337SLE - Systemic Lupus Erythematosus
DrugAZD0120
Chengdu Ucello Biotechnology Co., Ltd.
Early Phase 1
24
Chengdu
2025-12-10
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
16
Chengdu
2025-12-10
Not yet open
Abbisko Therapeutics Co, Ltd
Phase 1/2
110
Beijing, Zhengzhou, Wuhan, Shanghai, Chengde, Chengdu, Hangzhou
2025-12-10
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-12-10
Recruiting
Eli Lilly and Company
Phase 2
60
Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou
2025-12-08
Active, closed
Zai Lab (Shanghai) Co., Ltd.
Phase 3
108
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Beijing, Chengdu, Nanjing
2025-12-02
Not yet open
West China Hospital
Phase 3
528
Chengdu
2025-12-01
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
Active, closed
West China Hospital
Phase 1
20
Chengdu
2025-12-01
Not yet open
Du Zhenggui
Not applicable
150
Chengdu
2025-12-01
Not yet open
Allogeneic UCB-derived CAR-T for B-ALL
NCT07256353B-Cell Acute Lymphoblastic Leukemia, Adult
The General Hospital of Western Theater Command
Early Phase 1
50
Chengdu
2025-12-01
Recruiting
University of Electronic Science and Technology of China
Not applicable
120
Chengdu
2025-12-01
Not yet open
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
NCT07277504B-Cell Acute Lymphoblastic Leukemia, Adult
The General Hospital of Western Theater Command
Early Phase 1
50
Chengdu
2025-12-01
Not yet open
Du Zhenggui
Not applicable
379
Chengdu
2025-12-01
Not yet open
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Recruiting
AstraZeneca
Not applicable
3,000
Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian
2025-11-28
Recruiting
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Recruiting
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
DrugStapokibart
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang
2025-11-24
Recruiting
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Active, closed
MedtronicNeuro
Not applicable
61
Beijing, Guangzhou, Shanghai, Chengdu
2025-11-19
Recruiting
West China Hospital
Phase 4
232
Xi’an, Chengdu
2025-11-19
Recruiting
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07182565Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
DrugTS-1
West China Hospital
Phase 1/2
84
Xiamen, Chengdu
2025-11-18
Recruiting
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xi’an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Recruiting
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-11-14
Recruiting
Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study
NCT07601711Carbapenem-Resistant Acinetobacter Baumannii Infection, Bloodstream Infection, Pneumonia, Sepsis
DrugSulbactam -Durlobactam
Sichuan Provincial People's Hospital
Observational
200
Chengdu
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Haikou
2025-11-11
Recruiting
AstraZeneca
Phase 1
40
Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen
2025-11-10
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Sanofi
Phase 2
208
Chengdu, Guangzhou, Shanghai, Ürümqi
2025-11-06
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
DrugSintilimab
Guangdong Association of Clinical Trials
Phase 2
115
Guangzhou, Chengdu
2025-11-05
Recruiting
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
Wang Xin
Phase 1/2
60
Chengdu
2025-11-04
Recruiting
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
Grit Biotechnology
Phase 1/2
78
Shanghai, Chengdu
2025-11-01
Recruiting
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Active, closed
GlaxoSmithKline
Phase 3
750
Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming
2025-10-29
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
West China Hospital
Phase 1
9
Chengdu
2025-10-23
Recruiting
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
Haplo-Cord HSCT for AML/MDS
NCT07588360MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital
Not applicable
82
Fuzhou, Guangzhou, Chengdu, Beijing
2025-10-20
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
1,196
Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing
2025-10-20
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 2
48
Chengdu
2025-10-17
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
DrugsPretomanid·Bedaquiline·Linezolid·Moxifloxacin
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Recruiting
Hinova Pharmaceuticals Inc.
Phase 2
80
Beijing, Chengdu
2025-10-11
Recruiting
Non-pharmacological Auditory and Somatosensory Stimulation in Anesthetic Emergence
NCT07339618General Anesthetic, Electroencephalographic
West China Hospital
Not applicable
205
Chengdu
2025-10-11
Not yet open
West China Second University Hospital
Observational
40
Chengdu
2025-10-10
Recruiting
University of Electronic Science and Technology of China
Not applicable
140
Chengdu
2025-10-09
Recruiting
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Changsha, Nanjing, Xi'an, Chengdu
2025-10-08
Recruiting
Sanofi
Phase 3
980
Luoyang, Wuhan, Changshu, Chengdu, Jinhua, Luzhou, Shanghai
2025-10-08
Not yet open
West China Hospital
Observational
700
Chengdu
2025-10-05
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Recruiting
Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over
NCT07233616Chronic Venous Insufficiency, CVI, Radiofrequency Ablation, Octogenarians(Aged 80 and Over), Cohort Study
Chengdu University of Traditional Chinese Medicine
Observational
50
Chengdu
2025-10-01
Recruiting
West China Hospital
Observational
60
Chengdu
2025-10-01
Not yet open
Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus
NCT06663553Enlarged Uterus, Adenomyosis, Uterine Fibroids (UF)
West China Second University Hospital
Not applicable
210
Chengdu
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
283
Changsha, Chengdu, Wuhan
2025-10-01
Recruiting
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Not yet open
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Not yet open
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
20
Chengdu
2025-09-30
Recruiting
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Active, closed
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy
NCT07597733Refractory Chronic Inflammatory Demyelinating Polyneuropathy
DrugTelitacicept
Sichuan Academy of Medical Sciences
Not applicable
76
Chengdu
2025-09-26
Recruiting
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Recruiting
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Recruiting
AstraZeneca
Phase 1/2
164
Chengdu, Guangzhou
2025-09-24
Recruiting
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Harbin, Ningbo, Xiamen
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
DrugDelamanid
WestVac Biopharma Co., Ltd.
Phase 2
60
Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai
2025-09-19
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-09-17
Recruiting
Sanofi
Phase 3
942
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian
2025-09-17
Recruiting
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Recruiting
Candid Therapeutics
Phase 1
44
Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu
2025-09-16
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Shanghai, Chengdu
2025-09-16
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
West China Hospital
Phase 2
120
Chengdu
2025-09-13
Recruiting
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2025-09-13
Recruiting
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911SLE - Systemic Lupus Erythematosus
DrugCC312
CytoCares Inc
Phase 1
32
Chengdu
2025-09-11
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Recruiting
Pfizer
Phase 3
140
Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou
2025-09-10
Recruiting
West China Hospital
Phase 1/2
45
Chengdu
2025-09-10
By invitation
TAVR vs. SAVR Study of VitaFlow Liberty® for Severe BAV Stenosis
NCT06597188Aortic Stenosis, Bicuspid Aortic Valve (BAV)
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Not applicable
452
Chengdu
2025-09-08
Not yet open
Reinforcement Learned Automated Anesthesia Systems During Painless Abortion
NCT07132151Painless Abortion, Artificial Intelligence (AI), Ciprofol
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
167
Fuzhou, Jinjiang, Quanzhou, Shenzhen, Zhengzhou, Chengdu, Chongqing
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Beijing, Binhai, Changchun, Changsha, Chengdu, Chenzhou, Chifeng, Chongqing
2025-09-06
Recruiting
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
DrugGV20-0251
West China Hospital
Phase 1
10
Chengdu
2025-09-04
Recruiting
University of Electronic Science and Technology of China
Not applicable
40
Chengdu
2025-09-03
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Active, closed
Servier (Tianjin) Pharmaceutical Co. LTD.
Not applicable
62
Beijing, Qionghai, Chengdu
2025-09-02
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong
2025-09-02
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Recruiting
City University of Hong Kong
Not applicable
320
Xiamen, Guangzhou, Shenzhen, Chengdu
2025-09-01
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Not yet open
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
NCT07154108Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Sichuan University
Phase 1
40
Chengdu
2025-09-01
Recruiting
University of Electronic Science and Technology of China
Early Phase 1
250
Chengdu
2025-09
Not yet open
Sichuan Cancer Hospital and Research Institute
Not applicable
258
Chengdu
2025-09
Recruiting
Study of CM559 in Healthy Subjects
NCT07175506Healthy Subjects
Keymed Biosciences Co.Ltd
Phase 1
40
Chengdu
2025-09
Not yet open
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
20
Chengdu
2025-08-31
Recruiting
ScinnoHub Pharmaceutical Co., Ltd.
Phase 2
270
Chengdu
2025-08-27
Active, closed
a2 Milk Company Ltd.
Not applicable
100
Foshan, Guangzhou, Wuxi, Xuzhou, Chengdu
2025-08-25
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Not yet open
Lateral Positioning for Extubation After Adenotonsillectomy
NCT07108218Perioperative Respiratory Adverse Events, Adenoidectomy, Tonsillectomy, Children
Sichuan University
Not applicable
350
Chengdu
2025-08-20
Recruiting
Biotheus Inc.
Phase 2
100
Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2025-08-19
Recruiting
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Active, closed
Ion Beam Applications
Not applicable
47
Chengdu
2025-08-19
Recruiting
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
56
Chengdu
2025-08-18
By invitation
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Active, closed
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
180
Chengdu
2025-08-13
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
55
Chengdu
2025-08-11
Recruiting
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Rows per page Showing 1–500 of 1307
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,307 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

746 of the 1,307 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 170 have not yet opened recruitment, 364 are active but closed to new participants, and 27 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chengdu), 1,307 studies
PhaseStudiesRecruitingShare
Phase 343020632.9%
Phase 220311615.5%
Not applicable19910915.2%
Phase 114710611.2%
Observational1378110.5%
Phase 1/2112768.6%
Phase 2/334232.6%
Early Phase 123161.8%
Phase 422131.7%

Most active sponsors

Lead sponsors with the most studies (Chengdu)
Lead sponsorStudiesRecruiting
West China Hospital160102
AstraZeneca15485
Janssen Research & Development, LLC5820
Eli Lilly and Company4529
Hoffmann-La Roche4315
Sichuan University3926
Sanofi2715
University of Electronic Science and Technology of China2624
Boehringer Ingelheim2317
GlaxoSmithKline1811
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.